A new prognosis was issued: COPD-asthma market to reach $47bn in 2017
This $47bn sounds not bad!
The global market for asthma and chronic obstructive pulmonary disease (COPD) drugs is set to reach $47bn in 2017 according to a new report.
US market research firm BCC Research estimates that the market for prescription drugs in these respiratory areas will hit $38bn in 2012 before continuing growth at a compound annual rate of 4.4 per cent over the next five years.
This will be driven by the increasing prevalence of asthma and COPD due to the world’s increasingly aging population and rising pollution levels, says its Global Markets for Asthma & COPD Drugs report.
COPD comprises several chronic lung diseases that cause limitations in lung airflow and projections from the World Health Organization (WHO) see it being the third leading cause of death worldwide by 2030.
When broken down, the report predicts combination asthma/COPD drugs to be worth $17.4bn in 2012 and to reach $21.3bn in 2017.
Drugs with only an asthma indication will increase from $15,3bn in 2012 to $20.2bn in 2017, while COPD drug revenues will achieve a less significant growth from $5.3bn in 2012 to $5.6bn in 2017.
No comments:
Post a Comment